- Home
- ONCO
ONCO
Onconetix Inc.
as of 08-14-2026 4:00pm EST
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CINCINNATI |
| Market Cap: | 2.8M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 192.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | semi-annual |
| EPS: | -6.11 | EPS Growth: | 22.80 |
| 52 Week Low/High: | $0.09 - $6.73 | Next Earning Date: | 06-11-2026 |
| Revenue: | $815,371 | Revenue Growth: | -67.70% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.13 | Index: | N/A |
| Free Cash Flow: | -9706861.0 | FCF Growth: | N/A |
Compare ONCO vs Leading Stocks
See how ONCO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ONCO Onconetix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.